Research programme: plasma kallikrein inhibitors - KalVista Pharmaceuticals

Drug Profile

Research programme: plasma kallikrein inhibitors - KalVista Pharmaceuticals

Alternative Names: KVD 900

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vantia Therapeutics
  • Developer KalVista Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Hereditary angioedema

Most Recent Events

  • 14 Sep 2017 KalVista Pharmaceuticals announces intention to submit regulatory filing for KVD 900 for Hereditary angioedema by the end of 2017
  • 22 Nov 2016 KalVista Pharmaceuticals plans multiple clinical trials for Hereditary angioedema in United Kingdom
  • 07 Oct 2013 Preclinical development is ongoing in the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top